Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Liver Diseases

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 66 articles: HTML format

Single Articles

June 2024
1. GANAPATHI L, Cochran RL, Robbins GK, Barmettler S, et al
   Case 20-2024: A 73-Year-Old Man with Recurrent Fever and Liver Lesions.
   N Engl J Med. 2024;390:2309-2319.
   PubMed    
   
   
   
2. LOOMBA R, Hartman ML, Lawitz EJ, Vuppalanchi R, et al
   Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
   N Engl J Med. 2024 Jun 8. doi: 10.1056/NEJMoa2401943.
   PubMed     Abstract available
   
   
   May 2024
3. KOWDLEY KV, Levy C, Jones D
   Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis. Reply.
   N Engl J Med. 2024;390:1935-1936.
   PubMed    
   
   
   
4. HIRSCHFIELD GM, Kremer AE, Levy C
   Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis. Reply.
   N Engl J Med. 2024;390:1934-1935.
   PubMed    
   
   
   
5. IJICHI H
   Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis.
   N Engl J Med. 2024;390:1934.
   PubMed    
   
   
   
6. AREVALO-CANAS C, Arevalo-Serrano J
   Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis.
   N Engl J Med. 2024;390:1933-1934.
   PubMed    
   
   
   
7. NAJEM M, Dong E
   Esophageal Varices, White-Nipple Sign, and Portal Hypertensive Gastropathy.
   N Engl J Med. 2024;390:e47.
   PubMed    
   
   
   
8. HARRISON SA, Taub R
   A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis. Reply.
   N Engl J Med. 2024;390:1632-1633.
   PubMed    
   
   
   
9. SABET A
   A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis.
   N Engl J Med. 2024;390:1632.
   PubMed    
   
   
   February 2024
10. SCHNABL B
    PPAR Agonists in Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:855-858.
    PubMed    
    
    
    
11. HIRSCHFIELD GM, Bowlus CL, Mayo MJ, Kremer AE, et al
    A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:783-794.
    PubMed     Abstract available
    
    
    
12. ASSIS DN
    Advancing Second-Line Treatment for Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:853-854.
    PubMed    
    
    
    
13. CUSI K
    Selective Agonists of Thyroid Hormone Receptor Beta for the Treatment of NASH.
    N Engl J Med. 2024;390:559-561.
    PubMed    
    
    
    
14. HARRISON SA, Bedossa P, Guy CD, Schattenberg JM, et al
    A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
    N Engl J Med. 2024;390:497-509.
    PubMed     Abstract available
    
    
    December 2023
15. CAI S, Kuang M
    Clonorchis sinensis Liver Flukes.
    N Engl J Med. 2023;389:e57.
    PubMed    
    
    
    
16. LOOMBA R, Mansbach H, Margalit M
    Randomized Trial of Pegozafermin in NASH. Reply.
    N Engl J Med. 2023;389:2210.
    PubMed    
    
    
    
17. PATOULIAS D
    Randomized Trial of Pegozafermin in NASH.
    N Engl J Med. 2023;389:2209-2210.
    PubMed    
    
    
    November 2023
18. ROBBINS J, Halegoua-DeMarzio D, Basu Mallick A, Vijayvergia N, et al
    Liver Transplantation in a Woman with Mahvash Disease.
    N Engl J Med. 2023;389:1972-1978.
    PubMed     Abstract available
    
    
    
19. KOWDLEY KV, Bowlus CL, Levy C, Akarca US, et al
    Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
    N Engl J Med. 2023 Nov 13. doi: 10.1056/NEJMoa2306185.
    PubMed     Abstract available
    
    
    September 2023
20. RINELLA ME
    Pegozafermin for NASH - A Sprint to Start a Marathon.
    N Engl J Med. 2023;389:1044-1046.
    PubMed    
    
    
    
21. LOOMBA R, Sanyal AJ, Kowdley KV, Bhatt DL, et al
    Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH.
    N Engl J Med. 2023;389:998-1008.
    PubMed     Abstract available
    
    
    
22. ROBERTS EA, Schilsky ML
    Current and Emerging Issues in Wilson's Disease.
    N Engl J Med. 2023;389:922-938.
    PubMed    
    
    
    August 2023
23. VALLA DC, Garcia-Pagan JC
    Primary Budd-Chiari Syndrome. Reply.
    N Engl J Med. 2023;389:10.
    PubMed    
    
    
    
24. BORSANI O, Pietra D, Rumi E
    Primary Budd-Chiari Syndrome.
    N Engl J Med. 2023;389:10.
    PubMed    
    
    
    July 2023
25. DAUVILLIERS Y, Mignot E, Del Rio Villegas R, Du Y, et al
    Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1.
    N Engl J Med. 2023;389:309-321.
    PubMed     Abstract available
    
    
    June 2023
26. BALWANI M, Desnick RJ, Belongie K
    Dersimelagon in Erythropoietic Protoporphyrias. Reply.
    N Engl J Med. 2023;388:2492-2493.
    PubMed    
    
    
    
27. BARMAN-AKSOZEN J, Langendonk JG
    Dersimelagon in Erythropoietic Protoporphyrias.
    N Engl J Med. 2023;388:2492.
    PubMed    
    
    
    
28. GRANATA F, Dechant C, Falchetto R
    Dersimelagon in Erythropoietic Protoporphyrias.
    N Engl J Med. 2023;388:2491-2492.
    PubMed    
    
    
    April 2023
29. BALWANI M, Bonkovsky HL, Levy C, Anderson KE, et al
    Dersimelagon in Erythropoietic Protoporphyrias.
    N Engl J Med. 2023;388:1376-1385.
    PubMed     Abstract available
    
    
    
30. GARCIA-PAGAN JC, Valla DC
    Primary Budd-Chiari Syndrome.
    N Engl J Med. 2023;388:1307-1316.
    PubMed    
    
    
    February 2023
31. NADIM MK, Garcia-Tsao G
    Acute Kidney Injury in Patients with Cirrhosis.
    N Engl J Med. 2023;388:733-745.
    PubMed    
    
    
    
32. BHAN I, Schaefer EA, Bradley WR, Rodriguez-Lopez JM, et al
    Case 4-2023: A 56-Year-Old Man with Abnormal Results on Liver Testing.
    N Engl J Med. 2023;388:544-554.
    PubMed    
    
    
    
33. JU H, Liu C
    Cerebral Alveolar Echinococcosis.
    N Engl J Med. 2023;388:453.
    PubMed    
    
    
    January 2023
34. GOYAL L, Meric-Bernstam F, Hollebecque A, Valle JW, et al
    Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
    N Engl J Med. 2023;388:228-239.
    PubMed     Abstract available
    
    
    December 2022
35. VIEDMA-MARTINEZ M, Villegas Romero I
    Skin Necrosis after Transarterial Chemoembolization.
    N Engl J Med. 2022;387:2268.
    PubMed    
    
    
    
36. OLYNYK JK, Ramm GA
    Hemochromatosis.
    N Engl J Med. 2022;387:2159-2170.
    PubMed    
    
    
    August 2022
37. STRNAD P, Mandorfer M, Choudhury G, Griffiths W, et al
    Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency.
    N Engl J Med. 2022;387:514-524.
    PubMed     Abstract available
    
    
    July 2022
38. VERWEIJ N, Haas ME, Nielsen JB, Sosina OA, et al
    Germline Mutations in CIDEB and Protection against Liver Disease.
    N Engl J Med. 2022;387:332-344.
    PubMed     Abstract available
    
    
    January 2022
39. PATEL A, Tillman BF
    Spur-Cell Hemolytic Anemia.
    N Engl J Med. 2022;386:e6.
    PubMed    
    
    
    
40. SANYAL AJ, Van Natta ML, Tonascia J
    Nonalcoholic Fatty Liver Disease. Reply.
    N Engl J Med. 2022;386:296.
    PubMed    
    
    
    
41. FRANCQUE SM, Bedossa P, Abdelmalek MF
    Nonalcoholic Fatty Liver Disease. Reply.
    N Engl J Med. 2022;386:295-296.
    PubMed    
    
    
    
42. MIR BA, Majeed T, Chauhan A
    Nonalcoholic Fatty Liver Disease.
    N Engl J Med. 2022;386:295.
    PubMed    
    
    
    
43. XIA ML, Wang H
    Nonalcoholic Fatty Liver Disease.
    N Engl J Med. 2022;386:294-295.
    PubMed    
    
    
    
44. HORN P, Newsome PN
    Nonalcoholic Fatty Liver Disease.
    N Engl J Med. 2022;386:294.
    PubMed    
    
    
    December 2021
45. WILLETT LL, Bromberg GK, Chung R, Leaf RK, et al
    Case 38-2021: A 76-Year-Old Woman with Abdominal Pain, Weight Loss, and Memory Impairment.
    N Engl J Med. 2021;385:2378-2388.
    PubMed    
    
    
    November 2021
46. CHAPMAN MM, Muse VV, Mojica JE, Anahtar MN, et al
    Case 35-2021: A 50-Year-Old Woman with Pain in the Left Upper Quadrant and Hypoxemia.
    N Engl J Med. 2021;385:1995-2001.
    PubMed    
    
    
    October 2021
47. GARCIA-TSAO G
    Nonalcoholic Steatohepatitis - Opportunities and Challenges.
    N Engl J Med. 2021;385:1615-1617.
    PubMed    
    
    
    
48. SANYAL AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, et al
    Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.
    N Engl J Med. 2021;385:1559-1569.
    PubMed     Abstract available
    
    
    
49. FRANCQUE SM, Bedossa P, Ratziu V, Anstee QM, et al
    A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
    N Engl J Med. 2021;385:1547-1558.
    PubMed     Abstract available
    
    
    September 2021
50. CHANDRA A, Bhattacharjee MS
    Kayser-Fleischer Rings in Wilson's Disease.
    N Engl J Med. 2021;385:e46.
    PubMed    
    
    
    
51. BAJAJ JS, Kamath PS, Reddy KR
    The Evolving Challenge of Infections in Cirrhosis. Reply.
    N Engl J Med. 2021;385:1151-1152.
    PubMed    
    
    
    
52. HAIDAR G, Singh N
    The Evolving Challenge of Infections in Cirrhosis.
    N Engl J Med. 2021;385:1150-1151.
    PubMed    
    
    
    August 2021
53. ZOU Q, Li Y
    Hypervirulent Klebsiella pneumoniae.
    N Engl J Med. 2021;385:833.
    PubMed    
    
    
    
54. FREDRICK TW, Neto MBB, Johnsrud DO, Camilleri M, et al
    Turning Purple with Pain.
    N Engl J Med. 2021;385:549-554.
    PubMed    
    
    
    July 2021
55. KELLEY RK, Greten TF
    Hepatocellular Carcinoma - Origins and Outcomes.
    N Engl J Med. 2021;385:280-282.
    PubMed    
    
    
    
56. BUTTERS CT, Nash M
    Infantile Hepatic Hemangiomas.
    N Engl J Med. 2021;385:e10.
    PubMed    
    
    
    
57. NEWSOME PN, Sejling AS, Sanyal AJ
    Semaglutide or Placebo for Nonalcoholic Steatohepatitis. Reply.
    N Engl J Med. 2021;385:e6.
    PubMed    
    
    
    
58. DA BL, Satapathy SK
    Semaglutide or Placebo for Nonalcoholic Steatohepatitis.
    N Engl J Med. 2021;385:e6.
    PubMed    
    
    
    June 2021
59. BAJAJ JS, Kamath PS, Reddy KR
    The Evolving Challenge of Infections in Cirrhosis.
    N Engl J Med. 2021;384:2317-2330.
    PubMed    
    
    
    
60. WONG F, Curry MP, Sanyal AJ
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis. Reply.
    N Engl J Med. 2021;384:e90.
    PubMed    
    
    
    
61. CHINA L, Freemantle N, O'Brien A
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis. Reply.
    N Engl J Med. 2021;384:e90.
    PubMed    
    
    
    
62. RATHI S, Kalantri A, Kalantri S
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis.
    N Engl J Med. 2021;384:e90.
    PubMed    
    
    
    
63. CHAUHAN A, Sharma S, Saraya A
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis.
    N Engl J Med. 2021;384:e90.
    PubMed    
    
    
    
64. ELFEKI MA, O'Shea R, Carey WD
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis.
    N Engl J Med. 2021;384:e90.
    PubMed    
    
    
    April 2021
65. COHN A, Nehs M, Chan J, Vaidya A, et al
    Casting a Wide Net.
    N Engl J Med. 2021;384:e50.
    PubMed    
    
    
    
66. MCINNES IB, Anderson JK, Magrey M, Merola JF, et al
    Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.
    N Engl J Med. 2021;384:1227-1239.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.